Back to today’s briefing

Story perspectives

FDA Approves Game-Changing HIV Injection: $28K Price Shock

6/21/2025

37 2

Summary

Story summary

The FDA has greenlit lenacapavir (Yeztugo), a revolutionary injectable HIV prevention treatment that only needs two doses a year. With an impressive efficacy rate of over 99.9%, it marks a major leap from daily pills. However, its steep annual price of around $28,000 could hinder access, especially in low-income areas, prompting Gilead to seek affordable solutions for high-incidence countries.

1 of 1

Story summary

The FDA has greenlit lenacapavir (Yeztugo), a revolutionary injectable HIV prevention treatment that only needs two doses a year. With an impressive efficacy rate of over 99.9%, it marks a major leap from daily pills. However, its steep annual price of around $28,000 could hinder access, especially in low-income areas, prompting Gilead to seek affordable solutions for high-incidence countries.